Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, January 9, 2023
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
[ Mon, Jan 09th 2023
] - WOPRAI
Sun, January 8, 2023
[ Sun, Jan 08th 2023
] - WOPRAI
[ Sun, Jan 08th 2023
] - WOPRAI
Jonathan Wolleben Maintained (SPRB) at Buy and Held Target at $8 on, Jan 8th, 2023
Jonathan Wolleben of JMP Securities, Maintained "Spruce Biosciences, Inc." (SPRB) at Buy and Held Target at $8 on, Jan 8th, 2023.
Jonathan has made no other calls on SPRB in the last 4 months.
There is 1 other peer that has a rating on SPRB. Out of the 1 peers that are also analyzing SPRB, 0 agree with Jonathan's Rating of Hold.
This is the rating of the analyst that currently disagrees with Jonathan
- Hartaj Singh of "Oppenheimer" Maintained at Buy with Decreased Target to $8 on, Thursday, November 17th, 2022
